<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117672</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00553</org_study_id>
    <nct_id>NCT04117672</nct_id>
  </id_info>
  <brief_title>Antisecretory Factor In Severe Traumatic Brain Injury</brief_title>
  <acronym>AFISTBI</acronym>
  <official_title>Evaluation of Antisecretory Factor in Treatment of Severe Traumatic Brain Injury With Multimodal Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Siesjö</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lantmannen Medical AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Skane University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of Salovum, an egg yolk powder enriched for antisecretory
      factor, to standard care of participants with severe traumatic brain injury. Half of the
      participants will be administered Salovum while the other half will be given a placebo egg
      yolk powder, not enriched for antisecretory factor. Intracranial pressure (ICP), partial
      brain oxygen pressure (PtbO2), microdialysis of metabolites and inflammatory mediators and
      trauma intensity level (TIL) will be assessed in all patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral edema accounts for an essential part of the morbidity and mortality in severe
      traumatic brain injury but can also arise in other cerebral pathologies such as infectious
      and ischemic conditions such e.g. stroke and meningitis. Cerebral edema can lead to an
      elevated intracranial pressure (ICP) with impact on both perfusion and diffusion in the
      brain.

      AF (antisecretory factor) is a 41 kilodalton endogenous and essential protein with proposed
      antisecretory and anti-inflammatory effects. AF is homologous to S5A and Rpn10 proteins which
      are parts of the 26S proteasome subunit. AF also shows close homology to angiocidin a protein
      with reported anti-proliferative and anti-angiogenic properties. The AF protein is cleaved
      into several active peptides, one of which has been synthesized within a 16 amino acid
      peptide (AF-16) that has been used in animal experimental studies. Salovum® is a product
      based on the egg yolk powder B221®, and contains high levels of AF. Salovum® is classified as
      a food for special medical purposes (FSMP) by the European Food Safety Agency.

      AF has shown clinical effects in Mb Ménière, mastitis and meningitis. Experimentally AF-16
      and AF have been shown to reduce intracranial pressure and improve outcome in models of
      traumatic brain injury (TBI) and herpes encephalitis. Preliminary results show reduction of
      ICP and improved outcome in human traumatic brain injury. A randomized, prospective,
      double-blinded phase 2-3 in participants with severe traumatic head injury is ongoing at
      Tygerberg University Hospital, Cape Town, South Africa (ClinicalTrials.gov identification
      number: NCT03339505).

      The antisecretory factor is an endogenous protein and no antibody formation has been
      demonstrated in human administration. Although Salovum® has been given to hundreds of
      patients, no side effects have been recorded. Egg yolk allergy is a contraindication but no
      cases of triggered allergy have been reported.

      The mechanisms underlying the effects of antisecretory factor on cerebral edema are not
      clarified. Immune modulation through effects on myeloid cells, proteasome modulation and
      effects on ion pumps have been proposed.

      The present study intends to clarify mechanisms behind the proposed effect of antisecretory
      factor in cerebral edema In the present study participants with severe traumatic brain injury
      as defined in inclusion and exclusion criteria will be randomised to either treatment with
      Salovum or placebo egg powder during 5 days after enrolment. Randomisation will be performed
      in blocks and randomisation envelopes will be used with the number inside the envelope.
      Salovum and normal egg powder will be suspended with tap water and administered through the
      gastric feeding tube. All participants will receive standard care for severe TBI according to
      the treatment algorithm at the Neuro Intensive Care Unit (NICU), Department of Neurosurgery,
      Skåne University Hospital, Lund, Sweden. The algorithm prescribes invasive monitoring of ICP,
      PtbO2 and metabolites (cerebral microdialysis). As this algorithm includes stepwise
      co-interventions in order to control ICP and cerebral perfusion pressure (CPP) the TIL score
      will be used to compensate for the bias of increased co-interventions in either arm. At
      follow up patients will be assessed for mortality and Glasgow Outcome Scale-Extended (GOSE)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants with severe TBI and scheduled for multimodal monitoring will be randomised to active or placebo treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Egg powder enriched for antisecretory factor and placebo egg powder with the same color, taste and texture,</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ICP mean</measure>
    <time_frame>Change from baseline during intervention</time_frame>
    <description>Measured by an intracranial pressure sensor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICP area under curve</measure>
    <time_frame>Change from baseline during intervention</time_frame>
    <description>Measured by an intracranial pressure sensor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICP mean</measure>
    <time_frame>During intervention, 5 days</time_frame>
    <description>Measured by an intracranial pressure sensor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICP area under curve</measure>
    <time_frame>During intervention, 5 days</time_frame>
    <description>Measured by an intracranial pressure sensor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment intensity level</measure>
    <time_frame>Change from baseline during intervention</time_frame>
    <description>Treatment intensity level (TIL) scale. Minimum 0 (no intervention to control intracranial pressure (ICP)), maximum 38 points (maximum efforts to control ICP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment intensity level</measure>
    <time_frame>During intervention, 5 days</time_frame>
    <description>Treatment intensity level (TIL) scale. Minimum 0 (no intervention to control intracranial pressure (ICP)), maximum 38 points (maximum efforts to control ICP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracerebral oxygen partial pressure</measure>
    <time_frame>Change from baseline during intervention</time_frame>
    <description>Measured by an intracranial oxygen sensor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracerebral oxygen partial pressure</measure>
    <time_frame>During intervention, 5 days</time_frame>
    <description>Lactate/pyruvate ratio assessed by online microdialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cerebral metabolism</measure>
    <time_frame>Change from baseline during intervention</time_frame>
    <description>Lactate/pyruvate ratio assessed by online microdialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cerebral metabolism</measure>
    <time_frame>During intervention, 5 days</time_frame>
    <description>Lactate/pyruvate ratio assessed by online microdialysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory cytokine secretion</measure>
    <time_frame>Change from baseline during intervention</time_frame>
    <description>Interleukin-6 (Il-6), interleukin-8 (IL-8) and monocyte chemotactic protein (MCP-1) assessed from microdialysate and plasma by multiplex analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentration of inflammatory cytokines</measure>
    <time_frame>During intervention, 5 days</time_frame>
    <description>Interleukin-6 (Il-6), interleukin-8 (IL-8) and monocyte chemotactic protein (MCP-1) assessed from microdialysate and plasma by multiplex analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>At 30 days and 12 months</time_frame>
    <description>Mortality due to traumatic brain injury</description>
  </other_outcome>
  <other_outcome>
    <measure>Disability</measure>
    <time_frame>At 6 and 12 months</time_frame>
    <description>Assessed by Glagow Outcome Scale-Extended (GOSE). Minimum 1 (full recovery). MAXIMUM 8 (DEAD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentration of brain damage markers</measure>
    <time_frame>Change from baseline during intervention</time_frame>
    <description>Glial fibrillary acidic protein (GFAP) and neuron-specific enolase (NSE) assessed from microdialysate and plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentration of brain damage markers</measure>
    <time_frame>During intervention, 5 days</time_frame>
    <description>Glial fibrillary acidic protein (GFAP) and neuron-specific enolase (NSE) assessed from microdialysate and plasma</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Egg yolk powder not enriched for antisecretory powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salovum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Egg yolk powder enriched for antisecretory powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Salovum</intervention_name>
    <description>Active egg yolk powder</description>
    <arm_group_label>Salovum</arm_group_label>
    <other_name>Antisecretory factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo egg yolk powder</intervention_name>
    <description>Normal egg yolk powder</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Severe traumatic brain injury, Glasgow Outcome Scale (GCS) &lt;9 at admission to NICU.

        Clinical indication for insertion of intracranial pressure monitor, intracerebral oxygen
        pressure monitor and microdialysis catheter.

        Consultation with relatives or consent from guardians.

        Exclusion Criteria:

        Known egg yolk allergy.

        Unilateral or bilateral fixed and dilated pupil after initial operative intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Siesjö, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Siesjö, MD, PhD</last_name>
    <phone>+4646171274</phone>
    <email>peter.siesjo@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Cederberg, MD</last_name>
    <phone>+4646177655</phone>
    <email>david.cederberg@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skane University Hopsital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cederberg, MD</last_name>
      <email>david.cederberg@med.lu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Ilkhanizadeh S, Sabelström H, Miroshnikova YA, Frantz A, Zhu W, Idilli A, Lakins JN, Schmidt C, Quigley DA, Fenster T, Yuan E, Trzeciak JR, Saxena S, Lindberg OR, Mouw JK, Burdick JA, Magnitsky S, Berger MS, Phillips JJ, Arosio D, Sun D, Weaver VM, Weiss WA, Persson AI. Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma. Mol Cancer Res. 2018 May;16(5):777-790. doi: 10.1158/1541-7786.MCR-17-0413. Epub 2018 Feb 5.</citation>
    <PMID>29431617</PMID>
  </reference>
  <reference>
    <citation>Clausen F, Hansson HA, Raud J, Marklund N. Intranasal Administration of the Antisecretory Peptide AF-16 Reduces Edema and Improves Cognitive Function Following Diffuse Traumatic Brain Injury in the Rat. Front Neurol. 2017 Feb 14;8:39. doi: 10.3389/fneur.2017.00039. eCollection 2017.</citation>
    <PMID>28261150</PMID>
  </reference>
  <reference>
    <citation>Lönnroth I, Oshalim M, Lange S, Johansson E. Interaction of Proteasomes and Complement C3, Assay of Antisecretory Factor in Blood. J Immunoassay Immunochem. 2016;37(1):43-54. doi: 10.1080/15321819.2015.1042544.</citation>
    <PMID>25897558</PMID>
  </reference>
  <reference>
    <citation>Al-Olama M, Lange S, Lönnroth I, Gatzinsky K, Jennische E. Uptake of the antisecretory factor peptide AF-16 in rat blood and cerebrospinal fluid and effects on elevated intracranial pressure. Acta Neurochir (Wien). 2015 Jan;157(1):129-37. doi: 10.1007/s00701-014-2221-7. Epub 2014 Sep 24.</citation>
    <PMID>25248325</PMID>
  </reference>
  <reference>
    <citation>Johansson E, Al-Olama M, Hansson HA, Lange S, Jennische E. Diet-induced antisecretory factor prevents intracranial hypertension in a dosage-dependent manner. Br J Nutr. 2013 Jun 28;109(12):2247-52. doi: 10.1017/S0007114512004552. Epub 2012 Nov 16.</citation>
    <PMID>23153478</PMID>
  </reference>
  <reference>
    <citation>Hansson HA, Al-Olama M, Jennische E, Gatzinsky K, Lange S. The peptide AF-16 and the AF protein counteract intracranial hypertension. Acta Neurochir Suppl. 2012;114:377-82. doi: 10.1007/978-3-7091-0956-4_73.</citation>
    <PMID>22327727</PMID>
  </reference>
  <reference>
    <citation>Jennische E, Bergström T, Johansson M, Nyström K, Tarkowski A, Hansson HA, Lange S. The peptide AF-16 abolishes sickness and death at experimental encephalitis by reducing increase of intracranial pressure. Brain Res. 2008 Aug 28;1227:189-97. doi: 10.1016/j.brainres.2008.05.083. Epub 2008 Jun 11.</citation>
    <PMID>18586012</PMID>
  </reference>
  <reference>
    <citation>Lange S, Lönnroth I. The antisecretory factor: synthesis, anatomical and cellular distribution, and biological action in experimental and clinical studies. Int Rev Cytol. 2001;210:39-75. Review.</citation>
    <PMID>11580208</PMID>
  </reference>
  <reference>
    <citation>Johansson E, Lönnroth I, Lange S, Jonson I, Jennische E, Lönnroth C. Molecular cloning and expression of a pituitary gland protein modulating intestinal fluid secretion. J Biol Chem. 1995 Sep 1;270(35):20615-20.</citation>
    <PMID>7657640</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Skane University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Siesjö</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>traumatic brain injury</keyword>
  <keyword>cerebral edema</keyword>
  <keyword>antisecretory factor</keyword>
  <keyword>inflammatory cytokines</keyword>
  <keyword>cerebral oxygen monitoring</keyword>
  <keyword>intracranial pressure</keyword>
  <keyword>microdialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antisecretory factor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual patient data that underlie published results will be made available after publication.after de identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>From 3 months after publication to 24 months after publication.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

